Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Mongolia Healthcare Journal.
Press releases published on August 22, 2025
NMDP Named ‘Best Place to Work’ Fifth Year in a Row
MINNEAPOLIS, Aug. 22, 2025 (GLOBE NEWSWIRE) -- NMDPSM, a global nonprofit leader in cell therapy, announced the Minneapolis / St. Paul Business Journal honored the organization for the fifth consecutive year as a top workplace, notching 4th place in the ' …
CrazyBulk Supplements Bulking Stacks 2025: Crazy Bulk Launch “Safest Legal Steroid Alternatives” for Muscle Growth & Strength for Over 50's
new york, Aug. 22, 2025 (GLOBE NEWSWIRE) -- [New York, 22 AUGUST] — CrazyBulk, a well-known name in performance and fitness nutrition, is revolutionizing the bodybuilding community with its potent range of Bulking Supplements that enable athletes and …
Positron Corporation Announces New Corporate Headquarters and Strategic Redomiciling to Delaware
North Tonawanda, NY, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leader in molecular imaging technology and services, today announced that the Company had established a new corporate headquarters in …
Global Liquid Biopsy Market Set to Reach USD 7.05 Billion by 2030 | MarketsandMarkets™
Delray Beach, FL, Aug. 22, 2025 (GLOBE NEWSWIRE) -- The global liquid biopsy market, valued at US$3.65 billion in 2024, stood at US$4.03 billion in 2025 and is projected to advance at a resilient CAGR of 11.8% from 2025 to 2030, culminating in a forecasted …
Jyong Biotech Ltd. Participated in the 22nd Urological Association of Asia Congress to Display the Clinical Data for its Phase III Studies of BOTRESO and Phase II Study of MCS-8 (PCP)
New Taipei City, Taiwan, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”, “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated …
Beta-Glucan Market Set to Reach USD 800 Million by 2029, Driven by Expanding Applications Across Industries
Delray Beach, FL, Aug. 22, 2025 (GLOBE NEWSWIRE) -- According to MarketsandMarkets™, The report beta-glucan market size is projected to grow from $542 million in 2024 to $800 million by 2029, at a CAGR of 8.1%. This growth is being driven by the rising …
Global Surgical Sutures Market Poised to Reach USD 6.65 Billion by 2030 | MarketsandMarkets™
Delray Beach, FL, Aug. 22, 2025 (GLOBE NEWSWIRE) -- The global surgical sutures market, valued at US$4.56 billion in 2024, stood at US$4.84 billion in 2025 and is projected to advance at a resilient CAGR of 6.5% from 2025 to 2030, culminating in a …
BlossomHill Therapeutics Announces First Patient Dosed in Expansion Cohorts of the Phase 1/2 SOLARA Trial, Evaluating BH-30643 in Advanced EGFR-mutant Non-Small Cell Lung Cancer
SAN DIEGO, Aug. 22, 2025 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biotechnology company focused on the design and development of small molecule medicines for treating cancer and autoimmune diseases, today …
Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
PHILADELPHIA, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today …
Repligen Corporation to Present at Upcoming September Conferences
WALTHAM, Mass., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be attending three upcoming investor conferences. The Wells Fargo …
Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors
SAN DIEGO, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today …
CLINUVEL preparing upgrade of ADR program to Level II, Nasdaq uplist
Executive summary plan to upgrade American Depository Receipt (ADR) program (CLVLY) to a Level II ADR listed on Nasdaq, expected before the end of 2025 CLINUVEL’s primary listing on the ASX will remain unchanged as a result of the ADR uplist preparation of …